GlassScriptPhysician profile
Edward James Powers
NPI 1952755589
$4,812.67
in general payments reported to CMS, 2019-2025
27 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $150 · 2021: $520 · 2022: $578 · 2023: $435 · 2024: $1,427 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $876 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $875.77 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,600.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $727.28 | 2020-2025 | |
| Exeltis, USA INC. | $182.88 | 2021-2025 | Slynd |
| Organon LLC | $151.89 | 2022-2025 | Nexplanon |
| Astellas Pharma US INC | $140.87 | 2023-2024 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $116.74 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $111.77 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $84.29 | 2023-2025 | Gemtesa, Myfembree |
| Millicent US INC | $83.09 | 2021-2025 | Intrarosa, Femring, Femlyv |
| Daiichi Sankyo INC. | $79.92 | 2022-2023 | Injectafer |
| Myriad Women'S Health, INC. | $69.23 | 2023 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $52.14 | 2022 | |
| Avion Pharmaceuticals | $49.48 | 2022-2023 | NP Thyroid 60, Balcoltra |
| Therapeuticsmd, INC. | $47.95 | 2020-2021 | |
| Evofem Biosciences, INC. | $40.90 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $34.19 | 2021-2022 | |
| Coopersurgical, INC. | $31.11 | 2021-2024 | |
| Meditrina | $30.90 | 2025 | |
| Agile Therapeutics, INC. | $27.58 | 2022-2023 | Twirla |
| Merck Sharp & Dohme LLC | $26.80 | 2021 | |
| Pfizer INC. | $19.92 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.28 | 2022 | |
| Minerva Surgical, INC | $19.28 | 2021 | |
| Hologic Sales and Service, LLC | $17.66 | 2021 | |
| Merit Medical Systems INC | $17.16 | 2022 | |
| Sage Therapeutics, LLC | $16.94 | 2025 | Zurzuvae |
| Pacira Pharmaceuticals Incorporated | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.